Safety and pharmacokinetics of escalating doses of recombinant human nerve growth factor eye drops (HT006.2.2) in healthy subjects
Open Access
- 10 October 2025
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 215, 107314
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomesThe Ocular Surface, 2020
- Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic KeratopathyOphthalmology, 2020
- Pathogenese und Epidemiologie der neurotrophen KeratopathieDer Ophthalmologe, 2018
- Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic KeratitisOphthalmology, 2018
- Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic KeratitisOphthalmology, 2018
- Safety and Pharmacokinetics of Escalating Doses of Human Recombinant Nerve Growth Factor Eye Drops in a Double-Masked, Randomized Clinical TrialBioDrugs, 2013
- Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseasesCytokine & Growth Factor Reviews, 2004
- Clinical grading of corneal staining of non-contact lens wearersOphthalmic and Physiological Optics, 2001
- Regenerative effect of human recombinant NGF on capsaicin-lesioned sensory neurons in the adult ratBrain Research, 1999
- Complete recovery by nerve growth factor of neuropeptide content and function in capsaicin-impaired sensory neuronsBrain Research, 1996